- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07628621
Exercise On Bone Metabolism Markers In Chronic Kidney Disease (intervention)
June 1, 2026 updated by: Mona Mohamed Abdelkhalek, Badr University
Aerobic Versus Resistance Exercise On Bone Metabolism Markers In Chronic Kidney Disease
Sixty chronic kidney disease patients, Measurement of bone turnover markers done prior to the study and at the end of the study after 6 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Sixty chronic kidney disease patients, Measurement of bone turnover markers done prior to the study and at the end of the study after 6 months.
Participants included in two groups.
Group (A) received resisted exercise training on some resistance machines where; group (B) received treadmill exercise training.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Badr University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Non-smokers,
- no alcohol consumption
- no intake of hormone replacement therapy
- mass index ranged from 20-24 kg/m2.
Exclusion Criteria:
- diabetes disorders
- hypertension disorders
- cardiac disorders
- musculoskeletal disorders
- endocrine disorders
- intake of medications that may affect bone metabolism.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group (A)
Participants received resisted exercise training on some resistance machines
|
resistance exercises on some resistance machines, 3 sessions of exercise training /week
|
|
Experimental: group (B)
Participants received treadmill exercise training
|
treadmill aerobic exercise (intensity equal 60-80 % of each individual maximum heart rate)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum osteoprotegerin (OPG)
Time Frame: at baseline and after six month
|
An overnight fasting venous blood sample was drained, centrifuged and stored at -70 °C
|
at baseline and after six month
|
|
receptor activator of nuclear factor kappa B ligand
Time Frame: at baseline and after six month
|
An overnight fasting venous blood sample was drained, centrifuged and stored at -70 °C
|
at baseline and after six month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone mineral density (BMD)
Time Frame: at baseline and after six month
|
BMD of lumbar spine (L1-L4), proximal femur and distal radius was measured with dual-energy X-ray absorptiometry (DEXA).
|
at baseline and after six month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2025
Primary Completion (Actual)
May 30, 2026
Study Completion (Actual)
May 30, 2026
Study Registration Dates
First Submitted
June 1, 2026
First Submitted That Met QC Criteria
June 1, 2026
First Posted (Actual)
June 5, 2026
Study Record Updates
Last Update Posted (Actual)
June 5, 2026
Last Update Submitted That Met QC Criteria
June 1, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Pathological Conditions, Signs and Symptoms
- Renal Insufficiency, Chronic
Other Study ID Numbers
- SU.REC.2025(45H)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.